How Nurses Maximize the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at PeerView.com/USZ865. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and The Chrysalis Initiative. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.